The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC).
 
James M. Cleary
Honoraria - Agios
Research Funding - Merck
Travel, Accommodations, Expenses - Agios; Roche
 
Martin Henner Voss
Honoraria - Novartis
Consulting or Advisory Role - Alexion Pharmaceuticals; Calithera Biosciences; Exelixis; GlaxoSmithKline; Natera; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Genentech/Roche; Pfizer
Travel, Accommodations, Expenses - Novartis; Takeda
 
Funda Meric-Bernstam
Honoraria - DiaCarta
Consulting or Advisory Role - Clearlight Diagnostics; DarwinHealth; Genentech; Inflection Biosciences; Pieris Pharmaceuticals
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; Effective Pharmaceuticals; Genentech; Jounce Therapeutics; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Zymeworks
 
Cinta Hierro
No Relationships to Disclose
 
Rebecca Suk Heist
No Relationships to Disclose
 
Nobuya Ishii
Employment - Churchill Pharmaceuticals
 
Yulia Kirpicheva
Employment - Debiopharm Group
 
Valerie Nicolas-Metral
Employment - Debiopharm Group
 
Anna Pokorska-Bocci
Employment - Debiopharm Group
 
Anne Vaslin
Employment - Debiopharm Group
 
Werner Venetz
Employment - Debiopharm Group
 
Claudio Zanna
Employment - Debiopharm Group
 
Keith Flaherty
Stock and Other Ownership Interests - Clovis Oncology; Loxo
Consulting or Advisory Role - Adaptimmune; Aeglea Biotherapeutics; Amgen; Asana Biosciences; Bristol-Myers Squibb; Clovis Oncology; Genentech; Lilly; Loxo; Merck; miRNA Therapeutics; Novartis; Oncoceutics; Roche; Sanofi; Tioma Therapeutics
Research Funding - Novartis; Sanofi
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Celgene; Chugai Pharma; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche; Sanofi; Symphony Evolution; Taiho Pharmaceutical; Takeda
 
Jose Baselga
Leadership - Infinity Pharmaceuticals; Varian Medical Systems
Stock and Other Ownership Interests - GRAIL; Infinity Pharmaceuticals; Juno Therapeutics; PMV Pharma; Varian Medical Systems
Consulting or Advisory Role - Eli Lilly, Novartis; GRAIL